- Bristol Myers Squibb (BMY, Financial) unveils promising data on targeted protein degradation at the 2025 EHA Annual Congress.
- Highlighted are investigational agents mezigdomide, iberdomide, and golcadomide for multiple myeloma and non-Hodgkin lymphoma.
- Initial results of BCL6 ligand-directed degrader BMS-986458 show potential in addressing unmet needs in hematologic malignancies.
Bristol Myers Squibb (BMY) presented new data from its pioneering targeted protein degradation platform at the 2025 European Hematology Association (EHA) Annual Congress in Milan, Italy. The presentations focused on investigational CELMoD™ agents, including mezigdomide, iberdomide, and golcadomide, as well as the novel BCL6 ligand-directed degrader (BMS-986458) aimed at treating non-Hodgkin lymphoma.
During the congress, key findings included:
Mezigdomide (MEZI): In the MM-002 study, updated results revealed promising efficacy in relapsed/refractory multiple myeloma (RRMM) patients. For the MeziVd combination, the overall response rate (ORR) reached 85.7%. The median progression-free survival (PFS) was reported at 17.5 months, and neutropenia was the most common grade 3/4 treatment-emergent adverse event (TEAE).
Iberdomide (IBER): Findings from the MM-001 study showed an ORR of 88.9% in newly diagnosed multiple myeloma patients who are transplant-ineligible. Furthermore, 44% achieved minimal residual disease negativity, highlighting iberdomide's potential for durable response.
Golcadomide (GOLCA): Updated efficacy from studies on R/R follicular lymphoma (FL) and diffuse large b-cell lymphoma (DLBCL) emphasized enduring responses. The addition of rituximab in treatment regimens further bolstered ORR to 94% for R/R FL patients.
The first-in-human analysis of the BCL6 ligand-directed degrader, BMS-986458, underscored its potential with an ORR of 81% in non-Hodgkin lymphoma patients, demonstrating rapid and sustained BCL6 protein degradation.
Bristol Myers Squibb remains committed to harnessing innovative approaches in cancer therapy, aiming to transform treatment paradigms through research initiatives like these which address significant unmet medical needs in hematologic malignancies.
